BiotechTube

AZD0837 + Aspirin

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Persistent or Permanent Non-valvular Atrial Fibrillation

Conditions

Persistent or Permanent Non-valvular Atrial Fibrillation

Trial Timeline

Oct 1, 2007 → Oct 1, 2008

NCT ID
NCT00623779

About AZD0837 + Aspirin

AZD0837 + Aspirin is a phase 2 stage product being developed by AstraZeneca for Persistent or Permanent Non-valvular Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT00623779. Target conditions include Persistent or Permanent Non-valvular Atrial Fibrillation.

What happened to similar drugs?

4 of 8 similar drugs in Persistent or Permanent Non-valvular Atrial Fibrillation were approved

Approved (4) Terminated (1) Active (4)
✅Formoterol 12 mcg + Fluticasone propionate 100 mcg + Fluticasone propionate 250 mcg + Fluticasone propionate 500 mcg + PlaceboNovartisApproved
✅RivastigmineNovartisApproved
✅Omalizumab + PlaceboNovartisApproved
✅irbesartan + placeboSanofiApproved
🔄E7777 9 mcg/kgEisaiPhase 3
🔄CertoparinNovartisPhase 3
🔄Omalizumab + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00623779Phase 2Completed

Competing Products

20 competing products in Persistent or Permanent Non-valvular Atrial Fibrillation

See all competitors
ProductCompanyStageHype Score
E7777 9 mcg/kgEisaiPhase 3
40
DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solutionSanten PharmaceuticalPhase 2
35
Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment EAstraZenecaPhase 1
29
AZD0837 + VKA INR 2-3AstraZenecaPhase 2
35
Montelukast to placebo + Placebo to montelukastMerckPre-clinical
26
Everolimus + Tamoxifen + Letrozole + Medroxyprogesterone AcetateNovartisPhase 2
35
Formoterol 12 mcg + Fluticasone propionate 100 mcg + Fluticasone propionate 250 mcg + Fluticasone propionate 500 mcg + PlaceboNovartisApproved
35
CertoparinNovartisPhase 3
40
Omalizumab + PlaceboNovartisPhase 3
40
RivastigmineNovartisApproved
43
QAW039 capsules once daily for 28 days + Placebo to QAW039 capsules once daily for 28 days + Fluticasone propionate inhaler twice daily for 28 daysNovartisPhase 2
35
Indacaterol + Placebo to IndacaterolNovartisPhase 2
35
Omalizumab + PlaceboNovartisApproved
43
placebo + iv sildenafilPfizerPhase 3
40
etanercept + placeboPfizerPhase 2
35
SildenafilPfizerPhase 2
27
irbesartan + placeboSanofiApproved
39
iloprostBayerPre-clinical
15
IV Remodulin + PlaceboUnited TherapeuticsPhase 2
24
Nexagon® (lufepirsen) High Dose Concentration + Nexagon® (lufepirsen) Low Dose Concentration + Vehicle + Open-label Nexagon® (lufepirsen)GlaukosPhase 2
24